People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Healthtech, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Solenic Medical, Inc. | — | Healthtech | Seed | $9.5M | $17.2M | 2024 |
| Sfc Fluidics Inc. | — | Other | Pre-Seed | $2.8M | $571K | 2011 |
| BiologicsMD, LLC | — | Pharmaceuticals | Seed | $1.9M | $18.9M | 2016 |
| Atlantic Virtual Incubation Company, LLC | — | Other | Pre-Seed | $1.0M | $1.7M | — |
| Tesseract Structural Innovations, Inc. | — | Other | Pre-Seed | $788K | $1.4M | 2018 |
| TiFiber, Inc. | — | Other | Pre-Seed | $414K | $4.1M | 2013 |
| Cellia Science, Inc. | — | Other | Pre-Seed | $250K | $2.1M | 2022 |
| Biodetection Instruments Inc | — | Other | Pre-Seed | $125K | $2.9M | 2013 |
| Nutraceutical Innovations, Inc. | — | Other | Pre-Seed | $125K | $2.9M | 2013 |
| Osteovantage, Inc. | — | Other | Pre-Seed | $125K | $2.9M | 2013 |
Calvin Goforth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Calvin Goforth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Calvin Goforth | 4 | 25 |
| Mark Kidd | 4 | 5 |
| Mark Calvin Kidd | 3 | 10 |
| R. CALVIN GOFORTH | 2 | 10 |
| James Y. Lancaster | 2 | 3 |
| James Lancaster | 2 | 2 |
| David Greenberg | 1 | 13 |
| Clete Brewer | 1 | 8 |
| Tamir Meiri | 1 | 5 |
| Omid Moghadam | 1 | 5 |
| Ramsay Ball | 1 | 4 |
| Amit Mehta | 1 | 4 |
| Ramsay Calvin Ball | 1 | 4 |
| Ron Foster | 1 | 3 |
| Michael Thomas | 1 | 3 |
| Ron Calvin Foster | 1 | 3 |
| Robert Storey | 1 | 3 |
| Bryan Hosto | 1 | 3 |
| Fenel Eloi | 1 | 3 |
| Michael Artinger | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.